Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy
- 1 July 2020
- journal article
- research article
- Published by Elsevier BV in Life Sciences
- Vol. 252, 117646
- https://doi.org/10.1016/j.lfs.2020.117646
Abstract
No abstract availableFunding Information
- Mashhad University of Medical Sciences
This publication has 37 references indexed in Scilit:
- The Combination of a Low-Dose Chemotherapeutic Agent, 5-Fluorouracil, and an Adenoviral Tumor Vaccine Has a Synergistic Benefit on Survival in a Tumor Model SystemPLOS ONE, 2013
- Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinomaCancer Immunology, Immunotherapy, 2013
- The secret ally: immunostimulation by anticancer drugsNature Reviews Drug Discovery, 2012
- Doxorubicin in Combination with a Small TGFβ Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse ModelsPLOS ONE, 2010
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor ImmunityCancer Research, 2010
- Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in miceJCI Insight, 2010
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- OPTIMIZING DOSAGE OF KETAMINE AND XYLAZINE IN MURINE ECHOCARDIOGRAPHYClinical and Experimental Pharmacology and Physiology, 2007
- Caspase-dependent immunogenicity of doxorubicin-induced tumor cell deathThe Journal of Experimental Medicine, 2005
- Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune ActivityClinical Cancer Research, 2005